Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Turns To Insider Ian Read To Lead Into Post-Lipitor Era

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's election of Ian Read as president, CEO and director of the company sets the stage for a management transition at the firm, which has underperformed its peers on several measures in recent years.
Advertisement

Related Content

Pfizer CEO Read Will Pass The Torch To Bourla In 2019
People In Brief
People In Brief
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Capsugel Could Land In Private Equity Crosshairs If Pfizer Divests
Pfizer Exits Eight Manufacturing Sites And Slices Jobs In Six More
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer Set For “Fundamental And Sustained” Change Under New CEO Kindler

Topics

Advertisement
UsernamePublicRestriction

Register

PS104744

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel